Attività di ricerca
Ultime pubblicazioni:
-
Calabrò, L., P Caruso, F., Covre, A., R Noviello, T.M., F Lofiego, M., Tufano, R., et al. (2026). Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study. NATURE GENETICS, 58(5), 1100-1111 [10.1038/s41588-026-02580-4]. - dettaglio
-
Marabelle, A., O’Malley, D.M., Hendifar, A.E., Ascierto, P.A., Motola-Kuba, D., Penel, N., et al. (2025). Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. NATURE CANCER. - dettaglio
-
Di Giacomo, A.M., Subudhi, S., Vos, W., Andreatta, M., Carmona, S., Mctavish, W., et al. (2025). Perspectives on the role of “-Omics” in predicting response to immunotherapy. EUROPEAN JOURNAL OF CANCER, 220 [10.1016/j.ejca.2025.115393]. - dettaglio
-
Lofiego, M.F., Tufano, R., Bello, E., Solmonese, L., Marzani, F., Piazzini, F., et al. (2025). DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 44(1) [10.1186/s13046-025-03310-0]. - dettaglio
-
Solmonese, L., Lofiego, M.F., Fazio, C., Marzani, F., Piazzini, F., Bello, E., et al. (2025). The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. ONCOTARGETS AND THERAPY, 18, 995-1012 [10.2147/OTT.S527785]. - dettaglio
